11 Results for "

human A2780 ovarian

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "human A2780 ovarian" in MCE Product Catalog:

Cat. No.: HY-P99925
CAS No.: 1192578-27-0
Synonyms: REGN421

Target:  

Notch

Research Areas:  

Metabolic Disease Cancer

Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
loading...
    loading...
Cat. No.: HY-123888
CAS No.: 55625-78-0
Viomellein is a SUMOylation inhibitor with antibacterial and anticancer activities. Viomellein inhibits biofilm formation of strains produced from the fungus Aspergillus ochraceus from the Mediterranean sponge Agelas oroides. Viomellein exhibits cytotoxicity against A2780 human ovarian cancer cells with an IC50 value of 5.0 μM. Viomellein also inhibits SUMOylation of RanGAP1 (GTPase activating protein) with an IC50 of 10.2 μM .
loading...
    loading...
Cat. No.: HY-10226
CAS No.: 604769-01-9
Purity:  99.05%
Synonyms: R306465
Target:  

Apoptosis HDAC

Research Areas:  

Cancer

JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
loading...
    loading...
Cat. No.: HY-175857
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

HDAC-IN-92 is a pan-HDAC inhibitor with an IC50 of 12.58 µM in A2780 cells. HDAC-IN-92 demonstrates broad-spectrum, notable cytotoxic activity against a range of human cancer cell lines, including ovarian, liver, and breast carcinomas. HDAC-IN-92 causes apoptosis and demonstrates a notable decrease in tumor cell colony formation. HDAC-IN-92 inhibits the formation of blood vessels in the chick chorioallantoic membrane (CAM). HDAC-IN-92 exhibits anti-tumor effect in a 4T1 tumor-bearing mouse model. HDAC-IN-92 can be used for research targeting solid tumor .
loading...
    loading...
Cat. No.: HY-162721
Research Areas:  

Cancer

Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) .
loading...
    loading...
Cat. No.: HY-N9892
CAS No.: 666174-75-0
Guttiferone G inhibits recombinant human SIRT1 and SIRT2 (IC50: 9 and 22 μM, respectively). Guttiferone G is weakly cytotoxic in A2780 human ovarian cell line (IC50: 8.0 μg/mL). Guttiferone G can be isolated from Garcinia macrophylla .
loading...
    loading...
Cat. No.: HY-174160
Target:  

TAM Receptor Apoptosis

Research Areas:  

Cancer

MerTK-IN-2 (compound 15f) is an orally active MerTK inhibitor with an IC50 of 37.5 nM. MerTK-IN-2 can induce apoptosis. MerTK-IN-2 has antitumor activity with IC50 values of 1.79, 18.32, and 2.18 μM for human ovarian cancer cells A2780, breast cancer cells MDA-MB-231, and colon cancer cells HCT116, respectively .
loading...
    loading...
Cat. No.: HY-123034
CAS No.: 1189558-88-0
Target:  

CDK Bcl-2 Family Apoptosis

Research Areas:  

Cancer

CDKI-83 is a potent CDK9 and CDK1 inhibitor with Ki values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI50<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .
loading...
    loading...
Cat. No.: HY-182734
CAS No.: 350509-99-8
Target:  

CDK

Research Areas:  

Cancer

BMS-357075 is a pan-CDK inhibitor with CDK1 IC50 18 nM, CDK2 IC50 3 nM, CDK4 IC50 26 nM. BMS-357075 induces cytotoxicity in human ovarian cancer A2780 cells. BMS-357075 exhibits anticancer activity in mice against P388 murine leukemia. BMS-357075 can be used for the research of leukemia .
loading...
    loading...
Cat. No.: HY-N15168
CAS No.: 96853-54-2
3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene (Compound 3) is a stilbenoid compound found in Stuhlmannia moavi. 3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene exerts weak proliferative inhibitory activity and antimalarial activity with IC50 values of 54 and 27 μM against A2780 human ovarian cancer cells and Plasmodium falciparum. 3,4,5'-Trihydroxy-3'-methoxy-trans-stilbene can be used for researches of ovarian cancer and malaria .
loading...
    loading...
Cat. No.: HY-10226R
CAS No.: 604769-01-9
Synonyms: R306465 (Standard)
Research Areas:  

Cancer

JNJ-16241199 (Standard) is the analytical standard of JNJ-16241199 (HY-10226). This product is intended for research and analytical applications. JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
loading...
    loading...
  • 1